CLYM - Climb Bio, Inc.

QQQ $ 615.11 $ -4.04 (-0.65 %)

DIA $ 470.25 $ 0.57 (0.12 %)

SPY $ 672.36 $ -0.79 (-0.12 %)

TLT $ 90.13 $ 0.15 (0.17 %)

GLD $ 362.19 $ -1.27 (-0.35 %)

Previous Close

$ 1.88

Open

$ 1.94

Bid

$ 1.70 x 30

Ask

$ 1.99 x 40

Day's Range

$ 1.85 - $ 1.97

52 Week Range

$ 1.05 - $ 4.34

Volume

488,519

Average Volume

Market Cap

127.4M

Beta (5Y Monthly)

$ 0.25

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-14-2025	03-31-2025	10-Q
3	03-25-2025	12-31-2024	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-15-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K
8	11-14-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-06-2023	12-31-2022	10-K
12	11-14-2022	09-30-2022	10-Q
13	08-15-2022	06-30-2022	10-Q
14	05-16-2022	03-31-2022	10-Q
15	03-07-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	09-13-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Monday's A...
10/20/2025 21:08:49

Climb Bio To Showcase Preclinical And Long...
10/17/2025 11:05:42

Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated...

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity

Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

William Blair Initiates Coverage On Climb ...
10/16/2025 11:02:55

William Blair analyst Matt Phipps initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating.

BTIG Reiterates Buy on Climb Bio, Maintain...
10/16/2025 10:30:10

BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $8 price target.

HC Wainwright & Co. Initiates Coverage On ...
10/13/2025 11:21:01

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and annou...

Climb Bio Appoints Susan Altschuller As CFO
10/01/2025 11:05:28

BTIG Maintains Buy on Climb Bio, Raises Pr...
09/30/2025 11:26:30

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $7 to $8.

Climb Bio Reports Results From NHP Study C...
09/29/2025 11:03:17

CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and dosing interval data anticipated mid-year 2026...

BTIG Reiterates Buy on Climb Bio, Maintain...
09/22/2025 14:29:36

BTIG analyst Julian Harrison reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $7 price target.

Baird Initiates Coverage On Climb Bio with...
08/15/2025 14:18:59

Baird analyst Colleen Kusy initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target...

Climb Bio Q2 EPS $(0.13) Beats $(0.17) Est...
08/12/2025 11:10:44

Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by ...

12 Health Care Stocks Moving In Monday's P...
08/04/2025 12:08:38

Oppenheimer Initiates Coverage On Climb Bi...
06/06/2025 17:10:11

Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Pri...

Climb Bio Q1 EPS $(0.31) Misses $(0.15) Es...
05/14/2025 11:12:12

Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) b...

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
04/11/2025 21:06:36

Climb Bio Expects Cash Runway Through 2027
03/25/2025 20:10:00

Cash, cash equivalents and marketable securities were $212.5 million as of December 31, 2024, as compared to $106.8 million as ...

Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $...
03/25/2025 20:08:48

Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by ...

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
01/15/2025 12:05:48

Climb Bio Entered Technology Transfer And ...
01/10/2025 13:25:35

On January 8, 2025, Climb Bio, Inc. (the "Company") entered into a technology transfer and exclusive license agreement ...